Two candidate Ebola vaccines being tested in Liberia “appear safe” after phase two clinical trials, the US National Institutes of Health has announced.
The trials form part of the Partnership for Research on Ebola Vaccines in Liberia project, which has given the vaccines to 600 Liberians since 2 February.
The NIH’s National Institute of Allergy and Infectious Diseases finances the trial of one candidate, cAd3-EBOZ, together with its co-developer, pharmaceutical company GlaxoSmithKline.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.